BiVictriX Therapeutics Plc

Equities

BVX

GB00BNXH3K91

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 12:29:59 03/06/2024 pm IST			5-day change	1st Jan Change
11.5 ^GBX	0.00%		+4.55%	+9.52%

31/05	EARNINGS AND TRADING: CT UK High Income tops benchmark, ups dividend	AN
17/04	Bivictrix granted FDA orphan drug status for rare cancer treatment	AN

BiVictriX Therapeutics plc Announces Appointment of Michael Kauffman as Independent Non-Executive Director

January 17, 2022 at 12:30 pm IST

BiVictriX Therapeutics plc announced that it has appointed Dr Michael Kauffman, M.D., Ph.D. to its Board of Directors as an Independent Non-Executive Director with effect from 17 January 2022. He currently serves on the Boards of Karyopharm Therapeutics Inc, Verastem Oncology, Kezar Life Sciences and Adicet Bio.

Latest news about BiVictriX Therapeutics Plc

EARNINGS AND TRADING: CT UK High Income tops benchmark, ups dividend	31/05	AN
Bivictrix granted FDA orphan drug status for rare cancer treatment	17/04	AN
BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	17/04	MT
Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board	05/12	CI
Bivictrix selects final sequences for lead tumour programme	30/11	AN
BiVictriX Therapeutics plc Announces Pipeline Update on Lead Solid Tumour Programme, Bvx002	30/11	CI
BiVictriX patent boost; 4Global deal extended	15/11	AN
BiVictriX Obtains Japanese Patent for Acute Myeloid Leukemia Drug Conjugate	15/11	MT
Bivictrix Therapeutics Says Patent Granted In Japan Providing Further Broad Protection For BVX001	15/11	RE
Bivictrix says BVX001 increases survival rates by more than double	12/23/12	AN
BiVictriX Therapeutics' Blood Cancer Drug Delivers Extended Survival Rates in Trial	12/23/12	MT
Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid Leukaemia	12/23/12	RE
Bivictrix hires new CFO as Alex Hughes steps down after seven months	03/23/03	AN
BiVictriX Therapeutics Appoints New CFO, Chief Business Officer	03/23/03	MT
BiVictriX Therapeutics Plc Announces Chief Financial Officer Changes	03/23/03	CI
BiVictriX Therapeutics Plc Appoints Adrian Howd as Chief Business Officer	03/23/03	CI
AEW UK REIT appoints new chair; Oberon raises money	19/23/19	AN
Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Posts H1 Loss GBX-1.77	19/23/19	MT
BiVictriX Therapeutics Plc Reports Earnings Results for the Half Year Ended June 30, 2023	19/23/19	CI
AIM WINNERS & LOSERS: Jadestone Energy up on Montara repairs progress	23/23/23	AN
Bivictrix Therapeutics granted US patent for cancer drug BVX001	23/23/23	AN
BiVictriX Therapeutics Secures US Patent for Lead Asset	23/23/23	MT
Bivictrix Therapeutics raises GBP2.1 million through fundraise	20/23/20	AN
Bivictrix to raise more than GBP2 million via placing	19/23/19	AN
Bivictrix Therapeutics hails positive data in final leukaemia study	17/23/17	AN

Chart BiVictriX Therapeutics Plc

Duration

Period

More charts

Company Profile

BiVictriX Therapeutics plc is a drug discovery and development company. The Company is focused on leveraging clinical experience to develop highly selective cancer therapeutics. The Company generates a proprietary pipeline of Bi-Cygni Antibody Drug Conjugate (ADC) therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints, on tumour cells, which are largely absent from healthy cells. The Company utilizes these novel Bi-Cygni fingerprints, together with the Companyâs novel Antibody Drug Conjugate therapeutic design, to develop therapeutics to target cancers. Its pipeline includes BVX001, BVX002 and BVX003. Its lead program: BVX001 is a Bi-Cygni ADC designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with Acute Myeloid Leukaemia (AML), and in subpopulations of cancer cells from patients with other haematological cancers.

Sector

Biotechnology & Medical Research

Calendar

18/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.115 GBP

Average target price

0.66 GBP

Spread / Average Target

+473.91%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIVICTRIX THERAPEUTICS PLC	+9.52%	12.08M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research